Within approved clinical trial settings, the preparation of injectable investigational medicinal products (IMPs) must comply with Good Clinical Practice (GCP), the trial protocol, and local aseptic compounding policies
The decrease of total and primary BAs and the increase of fecal lithocholic acid are significant predictors of stool weight, frequency, and consistency
For example, patients with slower absorption patterns may benefit from abdominal injections consistently, while those with rapid absorption might alternate sites more frequently to maintain stable drug levels
Zepbound and Wegovy work in distinct ways to promote weight loss by targeting different aspects of metabolism and appetite regulation
Acknowledgements This work was partially supported by grants from JSPS (KAKENHI Grant Numbers JP21K08032 and 24K11270) to KS
Exendin-4 and sitagliptin protect kidney from ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction
